CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 8-K Event Results of operations
- SC 13G Stake Amended Statement of Ownership
- 4 Shares withheld for taxes CHIEF FINANCIAL OFFICER gave up 36,404 shares (to pay taxes)
- SC 13G/A Stake Amended Statement of Ownership
- 144 Insider Sale of Securities
- 8-K Event Code of ethics change
- 4 Shares withheld for taxes SVP, General Counsel gave up 28,310 shares (to pay taxes)
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Director sold 18,641 shares at $2.28 ($42,488)
- 144 Insider Sale of Securities
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change · Shareholder vote results
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 61,475 shares (grant or award)
- 4 Grant or award Director acquired 61,475 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 9 of 30 · 587 filings